Establishment of tacrolimus-induced diabetes in rat model and assessment of clinical treatments for post-transplant diabetes mellitus in liver transplant recipients

Clinical Laboratory

Volumn 59, Issue 7-8, 2013, Pages 869-874

  Niu, Y J ^a   Shen, Z Y ^b   Xu, C ^a   Li, C F ^c   Liu, X J ^a   Teng, Y Q ^a   Chen, H ^a   Li, L ^a   Cheng, H M ^a   Yang, X M ^a   Mao, S ^a  

^a GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b TIANJIN FIRST CENTRAL HOSPITAL   (China)

^c Chinese Medical Multimedia Press Co Ltd   (China)

Author keywords

Diabetes rat model; Glargine; Post transplant diabetes mellitus; Repaglinide; Tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NITROGEN; PROTEIN; REPAGLINIDE; TACROLIMUS; UREA; URIC ACID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHINESE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; DIET; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EXERCISE; EXPERIMENTAL DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FUNCTION; LIVER FUNCTION; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PANCREAS BIOPSY; PROTEIN BLOOD LEVEL; RAT; SIDE EFFECT; TACROLIMUS DIABETES MELLITUS; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS;

EID: 84883256023     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.120913     Document Type: Article

References (19)

1. Gomes MB, Cobas RA. Post-transplant diabetes mellitus. Diab Metab Syndr 2009;1:14-8.
2. Jelmesaeth J, Jessen T, Hartmann A. Diagnosing of PTDM. Transplantation 2003;75:1761.
3. Gonzalez-Posada JM, Hernandez D, Genis BB. Increased cardiovascular risk profile and mortality in kidney allograft recipients with post - transplant diabetes mellitus in Spain. Clin Transplant 2006;20:650-8. (Pubitemid 44383413)
4. International Diabetes Federation. Guidelines for the treatment and management of new-onset diabetes after transplantation. 2005.
5. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;47(suppl 1):S5-S10.
6. Alebiosu OC, Ayodele OE. Natural history and epidemiology of post transplantation diabetes mellitus. Afr Health Sci 2005;5:25560.
7. Mazali FC, Lalli CA, Alves-Filho G, Mazalli M. Posttransplant diabetes mellitus: Incidence and risk factors. Transplant Proc 2008;40:764-6. (Pubitemid 351608687)
8. Sharma A, Minz M, Singh S. Incidence of glucose metabolic abnormalities in Indian living renal allograft recipients on tacrolimus-based triple drug immunosuppression. Transplant Proc 2008; 40:2414-5.
9. Veroux M, Corona D, Giuffrida G, et al. New-onset diabetes mellitus after kidney transplantation: The role of immunosuppression. Transplant Proc 2008;40:1885-7.
10. Panz VR, Bonegio R, Raal FJ, et al. Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation. Transplantation 2002;73:587-90. (Pubitemid 34193621)
11. Nassar CA, Nassar PO, Andia DC, et al. Biochemical evaluation of glycemic levels of long-term tacrolimus therapy in rats. Braz Oral Res 2007;21:293-7.
12. Oetjen E, Baun D, Beimesche S, et al. Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Mol Pharmacol 2003;63:1289-95. (Pubitemid 36627223)
13. Filler G, Neuschulz I, Vollmer I, et al. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 2000;15:867-71. (Pubitemid 30312009)
14. Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996;98:2786-93. (Pubitemid 26427406)
15. Wu LW, Guo ZY, Tai Q, et al. Steroid elimination within 24 hours after orthotopic liver transplantation: effectiveness and tolerability. Hepatobiliary Pancreat Dis Int 2012;11:137-42.
16. Ju WQ, Guo ZY, Ling X, et al. Twenty-four hour steroid avoidance immunosuppressive regimen in liver transplant recipients. Exp Clin Transplant 2012;10:258-62.
17. Wang JH, Liang TB. Effects of Tacrolimus on insulin receptors of liver cell membrane in rats. J Clin Surg 2006;14:291-3.
18. Qing YL, Feng L. Mechanisms of diabetes mellitus induced with FK506 in SD rats models. Immunopharmacol Immunotoxicol 2009;31:675-81.
19. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplan.2005;19:291-8. (Pubitemid 40711959)